News Sentiment

DNA sentiment intelligence

Ginkgo Bioworks Holdings news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 65 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.91 Week of 17 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-13.0% over one week, -13.7% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Ginkgo Bioworks (NYSE: DNA) CFO logs RSU vesting and tax sell-to-cover

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -13.0% Price reacting lower
Trend fit Trend active -13.7% over four weeks
Fair value -66.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 50
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 18
Market source 10
simplywall.st 5
Sahm 4
TradingView 4
PR Newswire 3
Stock Traders Daily 2
The Globe and Mail 1

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 24
Regulatory and legal 3
Balance sheet 2
Guidance 1
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 65
Stock Titan Direct company coverage

Ginkgo Bioworks (NYSE: DNA) CFO logs RSU vesting and tax sell-to-cover

Ginkgo Bioworks (NYSE: DNA) CFO Steven P. Coen reported the vesting of 1,486 restricted stock units (RSUs) on July 16, 2026. Following this, he sold 752 shares of Class A Common Stock on July 17, 2026, at $7.903 per share. This sale was a non-discretionary "sell-to-cover" transac

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ginkgo Bioworks (NYSE: DNA) insider Steve Coen plans Class A stock sale

Ginkgo Bioworks insider Steve Coen has filed a Form 144 notice to sell 752 Class A common shares through Fidelity Brokerage Services. These shares originated from restricted stock vesting as compensation. The filing also reports previous Class A stock sales by Coen on April 17, 2

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 20:40
Source
Stock Titan
Sahm Direct company coverage

Ginkgo Bioworks Holdings' Stock Sinks To US$9.07, But Insiders Sold Even Lower

Ginkgo Bioworks Holdings, Inc.'s stock value dropped 12% in the last week, bringing it to US$9.07 per share. Despite this, company insiders who sold US$220k worth of stock last year did so at an average price of US$10.99, which was higher than the current share price. The article

Tone
Negative 37/100
Event
Market update
Published
10 Jul 2026 02:10
Source
Sahm
TradingView Direct company coverage

ETFs Investing in Ginkgo Bioworks Holdings, Inc. Class A Stocks

This article lists various ETFs that hold Ginkgo Bioworks Holdings, Inc. Class A stocks, providing details such as market value, weight, issuer, expense ratio, AUM, and 3-year NAV total return for each fund. The funds span different investment focuses, including artificial intell

Tone
Positive 60/100
Event
Market update
Published
05 Jul 2026 00:39
Source
TradingView
TradingView Direct company coverage

Ginkgo Bioworks Holdings, Inc. Class A Actuals & Estimates (NYSE:DNA)

This article provides an overview of Ginkgo Bioworks Holdings, Inc. (DNA) stock performance, financial data, and analyst forecasts. It covers recent stock price movements, market capitalization, earnings per share, revenue, and EBITDA. The report also highlights future earnings r

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

9L40 Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Ginkgo Bioworks Holdings, Inc. Class A (9L40) for 2027, based on analyst opinions. It outlines historical price movements, financial reporting details including earnings and revenue, and key company metrics like EBITDA and emp

Tone
Negative 41/100
Event
Earnings
Published
26 Jun 2026 01:39
Source
TradingView
Stock Traders Daily Direct company coverage

The Technical Signals Behind (DNA) That Institutions Follow

This article analyzes Ginkgo Bioworks Holdings Inc. (NYSE: DNA) using AI-generated technical signals. It highlights a near-term strong sentiment potentially challenging persistent mid- and long-term weakness, noting an exceptional 84.7:1 risk-reward short setup. The analysis prov

Tone
Negative 28/100
Event
Market update
Published
21 Jun 2026 00:26
Source
Stock Traders Daily
Stock Titan Direct company coverage

Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant

Ginkgo Bioworks Holdings, Inc. director Henry Christian O was granted 25,000 restricted stock units (RSUs), as reported in a Form 4 filing. These RSUs represent a contingent right to receive one share of Class A common stock each and will vest on the earlier of June 11, 2027, or

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 04:10
Source
Stock Titan
Stock Titan Direct company coverage

Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA)

Ginkgo Bioworks (NYSE: DNA) director Ross Fubini was granted 25,000 Restricted Stock Units (RSUs) on June 11, 2026, as reported in a recent SEC Form 4 filing. These RSUs, which have no cash exercise price, will vest on the earlier of June 11, 2027, or the day before the next annu

Tone
Neutral 50/100
Event
Balance sheet
Published
16 Jun 2026 04:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs

Ginkgo Bioworks director Sri Kosuri was granted 25,000 restricted stock units (RSUs) on June 11, 2026, as equity compensation. These RSUs, which represent contingent rights to receive Class A common stock, will vest on the earlier of June 11, 2027, or the day before the next annu

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs

Ginkgo Bioworks director Harry Sloan was granted 25,000 restricted stock units (RSUs) on June 11, 2026. These RSUs, which represent a contingent right to receive one share of Class A common stock per RSU, will vest on the earlier of June 11, 2027, or the day before the next annua

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:10
Source
Stock Titan
The Globe and Mail Direct company coverage

Ginkgo Bioworks Shareholders Back Board, Governance Structure

Ginkgo Bioworks Holdings (DNA) shareholders affirmed the company's existing board, governance structure, and executive compensation at their 2026 annual meeting. The strong shareholder turnout and approval signal stability for investors. Despite weak financial performance noted b

Tone
Positive 63/100
Event
Regulatory and legal
Published
14 Jun 2026 18:39
Source
The Globe and Mail
Stock Titan Direct company coverage

Ginkgo Bioworks (NYSE: DNA) shareholders approve directors, Deloitte and executive pay

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) shareholders approved the election of all six director nominees, ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, and gave advisory approval to the compensation of the company's named executiv

Tone
Neutral 50/100
Event
Regulatory and legal
Published
12 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Austin Che files Form 144 to sell Class A shares | DNA SEC Filing - Form 144

Austin Che, an insider at Ginkgo Bioworks Holdings, Inc. (DNA), has filed a Form 144 indicating proposed sales of Class A shares. The filing details multiple sale notifications through Fidelity Brokerage Services LLC, including sales of 2,200 shares on March 11, 2026, for $13,882

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 15:09
Source
Stock Titan
Stock Traders Daily Direct company coverage

Precision Trading with Ginkgo Bioworks Holdings Inc. Class A (DNA) Risk Zones

This article analyzes Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA) using AI models, highlighting a mid-channel oscillation pattern and an exceptional 133.0:1 risk-reward setup. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailor

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 23:18
Source
Stock Traders Daily
TMX Newsfile Direct company coverage

Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is reminding shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) about an upcoming deadline for a securities fraud class action lawsuit. Investors who suffered significant losses during the class period of May 11, 2021, to October 5, 2021

Tone
Negative 18/100
Event
Regulatory and legal
Published
02 Jun 2026 07:39
Source
TMX Newsfile
Simply Wall Street Direct company coverage

Ginkgo Bioworks Holdings (NYSE:DNA) - Stock Analysis

This Simply Wall St analysis provides a comprehensive overview of Ginkgo Bioworks Holdings (NYSE:DNA), detailing its valuation, growth prospects, past performance, and financial health. The article highlights recent corporate announcements, earnings reports, and analyst revisions

Tone
Negative 37/100
Event
Earnings
Published
27 May 2026 20:39
Source
Simply Wall Street
Stock Titan Direct company coverage

Ginkgo Bioworks (NYSE: DNA) insider logs RSU vesting and small tax-related share sale

Ginkgo Bioworks (NYSE: DNA) insider Steven P. Coen reported routine equity compensation activity including RSU vesting and a related tax-related share sale. Coen exercised awards for 743 shares of Class A Common Stock at $0.00 per share and subsequently sold 307 shares at $8.334

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Steve Coen (DNA) files Form 144 to sell 307 Class A shares

Steve Coen has filed a Form 144 to sell 307 Class A shares of Ginkgo Bioworks Holdings, Inc. (DNA), stemming from a Restricted Stock Vesting event on May 21, 2026. This filing also discloses previous dispositions by Coen, totaling 33,903 shares between March and April 2026. The t

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person

Viking Global Investors and its affiliated entities have reported a shared beneficial ownership of 3,577,128 shares of Class A Common Stock in Ginkgo Bioworks Holdings, Inc. (DNA), representing 7.1% of the outstanding shares as of March 31, 2026. This Schedule 13G/A amendment als

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA)

Austin Che has filed a Form 144 to report proposed sales of Class A shares of Ginkgo Bioworks Holdings, Inc. (DNA). The filing indicates an intent to sell 2,200 Class A shares linked to a Restricted Stock Vesting from October 20, 2022. It also discloses sales totaling 45,293 shar

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 15:09
Source
Stock Titan